Albutrix is a specialized protein supplement developed specifically for people with chronic kidney disease. Clinically it is classified as a keto acid analog — a category of medical nutrition designed to provide all the essential amino acids the body needs from protein, through a metabolic pathway that produces far less nitrogen waste than standard protein supplements.
Why Standard Protein Supplements Are Wrong For CKD
When the body processes dietary protein, it produces nitrogen waste — primarily urea, measured in blood tests as BUN (blood urea nitrogen). In CKD, reduced filtration means this nitrogen load contributes directly to hyperfiltration and disease progression. Standard protein supplements — whey, plant protein, amino acid blends — generate the same nitrogen waste as dietary protein. They are not appropriate for CKD patients on a protein-restricted protocol.
Keto acid analogs were developed specifically to solve this problem: provide complete essential amino acid nutrition without the nitrogen burden.
What Makes Albutrix Clinically Distinct
Albutrix is not simply a keto acid analog — it is the only one clinically proven in human patients to improve eGFR and achieve therapeutic BUN levels when used with the Kidneyhood very low protein diet.
- Lowest nitrogen content of any protein supplement in its category — less than 200 mg nitrogen per daily dose
- Lowest supplemental calcium (S3 and S4) — aligned with NKF guidance, safe for diabetics, no blood sugar spikes
- Highest magnesium content of any keto acid analog — associated with improved survival outcomes in CKD research
- No maltodextrin or high-glycemic fillers
- Stage-specific formulas (S3, S4, S5) precisely matched to current GFR level
- Ships internationally without a prescription — the only KAA with this level of global accessibility
- Manufactured in FDA-registered, lot-tested US facilities
- Protected by US Patent 11,253,496 and EU Patent 3,799,724
Proven In Humans Using Drug-Equivalent Clinical Endpoints
Albutrix is not a supplement with theoretical benefits. It has been studied in human CKD patients — informed consent, HIPAA-compliant data collection, standard statistical methodology — measuring eGFR, BUN, and creatinine. These are the identical endpoints the FDA requires for kidney disease drug approval. A statistically significant dose-response relationship (p = 0.002) between achieved BUN level and eGFR improvement was identified.
In documented clinical studies: 80% of patients improved eGFR | 92% reduced BUN | 86% lowered creatinine
Selecting Your Formula
FDA Registration
Albutrix is an FDA-registered medical food under 21 U.S.C. 360ee(b)(3) — the Orphan Drug Act. Medical foods are a distinct regulatory category from drugs. Albutrix meets all FDA requirements for medical foods and is manufactured in FDA-registered, lot-tested US facilities.